ISPOR 16th Annual International Meeting

May 21-25, 2011 • Hilton Baltimore • Baltimore, MD, USA

Health Care Reform and Comparative Effectiveness Research – Where Have We Been and Where Are We Going?

CALL FOR ABSTRACTS

Abstract Submission Deadline: January 13, 2011

Early Registration Deadline: April 5, 2011

MEETING PROGRAM COMMITTEE

Program Committee Chair
Mark S. Roberts MD, MPP, Professor and Chair, Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health & Professor of Medicine, Industrial Engineering and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA

Research Review Committee Co-Chairs
Murtuza Bharmal PhD, MS, Director, Quintiles, Rockville, MD, USA
Teresa B. Gibson PhD, MS, MA, Director, Health Outcomes, Thomson Reuters (Healthcare), Ann Arbor, MI, USA
Yi Yang MD, PhD, Assistant Professor of Pharmacy Administration and Research Assistant Professor, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, USA

Workshop Review Committee Co-Chairs
John F.P. Bridges PhD, Assistant Professor, Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD, USA
Mark Cziraky PharmD, Vice President, Research Development and Operations, HealthCore, Inc., Wilmington, DE, USA

Issue Panel Review Committee Co-Chairs
Rachael Fleurence PhD, Senior Research Scientist, Center for Health Economics and Science Policy, United BioSource Corporation, Bethesda, MD, USA
Sheldon Kong PhD, Executive Director and Head, Global Outcomes Research, Merck & Company, Inc., Whitehouse Station, NJ, USA

Decision-maker Case Study Review Committee Co-Chairs
TBD

MEETING PROMOTIONAL OPPORTUNITIES

EXHIBIT
Register now! Over 2300 attendees in 2010!
Present your products and services to key outcomes researchers and health care decision-makers in pharmaceutical, medical device & diagnostics, biotechnology industries, clinical practice, government agencies, academia, and health care organizations.
Benefits to Exhibitors:
• Listing & 1/4 page ad in the Program & Schedule of Events and on the ISPOR website
• One complimentary registration per exhibit booth
• Pre-registrant mailing labels

ADVERTISE
Advertise in the Program & Schedule of Events!
• Company promotion
• Job opportunities
• Publications
• Journals
- Full page, full color advertising available
- 1/4, 1/2, and full page, one color advertising available. Prices start from $900.

Advertising Deadline: September 27, 2011

SPONSOR
Increase your visibility!
Give your company increased prominence.
Benefits to Sponsors:
• Sponsorship recognition at the plenary sessions
• Event signage
• Listing & 1/4 page ad in the Program & Schedule of Events
• Listing & 1/4 page ad on the ISPOR website
• One complimentary registration
• Preferential exhibit booth location

FOR MORE INFO: www.ISPOR.ORG
SUNDAY, MAY 22, 2011

(All Day Course) 8:00 AM - 12:00 PM
Bayesian Analysis – Advanced

This course focuses on the use of Markov Chain Monte Carlo methods in conducting policy-relevant outcomes research. Participants engage in hands-on exercises and address certain methodological issues, concluding with a discussion on the role of Bayesian methods in policy-making.

Applications in Using Large Databases

This course reviews 3 databases – GPRD (UK database), GE Centricity electronic medical record (EMR) and Medicaid (US databases). Each database is discussed in-depth including directions on accessing information and how researchers utilize this information.

Patient Registries

This course reviews patient registries and their applications in identifying “real world” clinical, safety, and patient-perspective issues. The pros and cons of registry data and how it can support health economics / outcomes research initiatives and decision making are addressed. Registry strategy, design, operations and measures of program success are discussed.

Conjoint Analysis

This course introduces the conceptual basis for quantifying decision-maker preferences for medical interventions and the practical design and analytical issues that must be addressed to obtain valid empirical preference estimates.

Utility Measures

This course introduces utility measures to support economic evaluations. Concepts of health-related quality of life are discussed in terms of their differences and similarities. We explore methods used to capture utilities such as standard gamble, time trade off and rating scales, and discuss instruments to measure quality of life and their pros and cons, such as the EQ-5D, Health Utilities Index and SF-36. Finally we describe requirements and preferences of different reimbursement agencies around the world.

Case Studies in Pharmaceutical/Biotech Pricing II – Advanced

Case studies lead participants through key steps of new product pricing, focusing on the need to thoroughly analyze the business environment, its constraints and opportunities, and the need to integrate pricing, reimbursement and PE strategies for the new product with clinical development and marketing strategies.

Statistical Considerations in Health Economic Evaluations

This course discusses effect of distributional assumptions, analyzing univariate and multivariable analysis data, analyzing censored data, sample size and power calculations, sampling uncertainty, point estimates for variables, net monetary benefit, and confidence intervals for cost-effectiveness ratios.

Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products

There is significant and growing interest among payers and providers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. Theory and practice, including incentives and barriers, of these arrangements will be analyzed along with several examples of performance-based schemes from Europe, the United States, and Australia.

Outcomes Research for Medical Devices and Diagnostics

This course presents outcomes research practices specifically tailored for the medical device and diagnostics technology environment. Outcomes research for medical devices and diagnostics is differentiated from other health care interventions. The evidence hierarchy for medical devices and diagnostic procedures is discussed.

Propensity Scores and Observational Studies of Treatment Effect

This course outlines concerns about bias and explains the methods for causal inference in observational studies. We explain how propensity scores can reduce bias. Risk adjustment models, confounding, pros and cons of standard adjustment and propensity scoring methodology are discussed.

Advanced Patient-Reported Outcomes Assessment – Psychometric Methods

This course discusses psychometric analysis and the application of various techniques (structural equation modeling, factor analysis, and item response theory) in testing patient-reported outcomes instruments, measures and construct / criterion validity.

Establishing the Content Validity of Patient-Reported Outcomes (PRO) Instruments

This course focuses on requirements for establishing the content validity of PRO instruments. Content covers definitions of evidence requirements, issues necessitating clarity, and logistical needs for gathering acceptable evidence. Participants will take part in practical exercises as part of the iterative process to determine and establish evidence of content validity for PRO instruments.

Advanced Decision Modeling for Health Economic Evaluations

Key aspects in the development of decision modeling, how models can be made probabilistic to capture parameter uncertainty, and how to analyze and present results are discussed. How results should be reported and decisions should be made (including decisions with uncertainty, expected value of perfect information [EVP], and expected value of sample information [EVS]) are presented.
CALL FOR ABSTRACTS

Abstract Submission Begins: October 13, 2010
Abstract Submission Deadline: January 13, 2011

SUBMISSION INSTRUCTIONS

All abstracts and proposals MUST be submitted through ISPOR’s online abstract submission system by January 13, 2011. Abstracts accepted for other ISPOR meetings can NOT be submitted and research published or presented at other national or international meetings is discouraged.

SUBMISSION INSTRUCTIONS, EXAMPLES & SPECIFIC EVALUATION CRITERIA AVAILABLE AT www.ispor.org

RESEARCH ABSTRACTS

Outcomes research on all health care interventions (including drugs, devices, behavioral modification programs, surgery, disease prevention, gene therapy, screening, diagnostic procedures and health education) on all diseases or health disorders are considered. Research abstracts (except for conceptual papers) must be organized by OBJECTIVES, METHODS, RESULTS, CONCLUSIONS. All accepted research abstracts are published in Value in Health as submitted. Accepted research is presented as a 15 minute podium presentation or poster presentation (with a poster author discussion hour). Abstracts are evaluated on the quality of the study (or concept) and quality of the abstract presentation. Research topics include: Clinical Outcomes Studies, Cost Outcomes Studies, Patient-Reported Outcomes Studies, Health Policy Studies & Beyond Drug Interventions, Methods/Health Policy Concepts and Research on Methods. See the ISPOR website for research subtopics.

HEALTH CARE DECISION-MAKER CASE STUDY ABSTRACTS

Health care decision-maker case study abstracts must describe an organization’s attempt to integrate cost or outcomes research information into their health care organization’s processes and procedures. Case Study abstracts must be organized: ORGANIZATION, PROBLEM OR ISSUE ADDRESSED, GOALS, OUTCOMES RESEARCH USED IN THE DECISION, RESULTS, LESSONS LEARNED. Negative as well as positive results are encouraged. Accepted case studies are presented as a 20 minute podium presentation or poster presentation (with a poster author discussion hour). THE PRESENTER MUST BE A HEALTH CARE DECISION-MAKER.

WORKSHOP PROPOSALS

Workshop proposals should show novel and innovative experiences in the conduct of outcomes research (including, but not limited to, experiences with conjunction analysis, large database analysis, modeling, observational studies, record review, surveys, sensitivity analysis and patient registries) or novel and innovative experiences in the use of outcomes research (clinical, economic, or patient-reported/preference-based outcomes) in health care policy development. Workshop proposals must be organized by DISCUSSION LEADERS, PURPOSE, DESCRIPTION. Accepted workshops are one hour in duration with a minimum of 2 and maximum of 4 discussion leaders and more than one organization must be represented. An audience interactive element must be included in the proposal and during the workshop. Workshop topics include: Clinical Outcomes Research, Economic Outcomes Research, Patient-Reported/Preference-based Outcomes Research, Use of Real World Data, Health Policy Development Using Outcomes Research. See the ISPOR website for workshop subtopics.

ISSUE PANEL PROPOSALS

Issue panel proposals should show real debate on new or controversial issues in health economic/pharmacoeconomics and outcomes research or real debate on the use of outcomes research in health care decision-making. Issue panel proposals must be organized MODERATOR, PANELISTS, ISSUE, OVERVIEW. An accepted issue panel is one hour in duration with a moderator and 2-3 panelists representing different organizations. Panelists should present distinct views about the topic. Issue Panel topics are: Clinical Outcomes Research Issues, Economic Outcomes Research Issues, Patient-Reported Outcomes Research Issues, Health Policy Development Using Outcomes Research Issues. See the ISPOR website for issue panel subtopics.

PRELIMINARY PROGRAM

Monday, May 23: 8:00AM - 8:30PM
FIRST PLENARY SESSION: HEALTH CARE REFORM IN THE UNITED STATES - ONE YEAR LATER
In 2010, US Congress passed major health care reform legislation [the “Affordable Care Act” and the “Reconciliation Act”]. The Medicare prescription drug “doughnut hole” will be phased out. Employers will be penalized if they do not offer health care coverage and US citizens are required to have “health care coverage” by 2014. Small businesses can purchase qualified coverage via state-based health insurance exchanges by 2014. How will these changes affect health care management organizations and providers and health technology producers (drug, device, and diagnostics)? These questions will be addressed during this plenary session.

*20 Research Podium Presentations * 14 Workshops * 6 ISPOR Group Forums * 5 Issue Panels * Exhibits * 350 Research Poster Presentations – Session I

Tuesday, May 24: 8:00AM - 8:00PM
SECOND PLENARY SESSION: COMPARATIVE EFFECTIVENESS RESEARCH & USA’S PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
In the American Recovery and Reinvestment Act (ARRA) of 2009, US Congress appropriated $1.1 billion to jump-start the nation’s efforts to accelerate comparative effectiveness research (CER). The USA’s Institute of Medicine (IOM) recommended national priorities for research questions to be addressed by CER and these funds. How were these funds spent? Will the results from these studies impact how health care decisions are made? In the Patient Protection and Affordable Care Act of 2010, US Congress established the Patient-Centered Outcomes Research Institute (PCORI) to identify priorities for and establish, update and carry out a national comparative outcomes research project agenda. What are the research priorities? Will they differ from the IOM recommendations? Who will conduct the studies? How will the study results impact health care? This plenary session will address each of these questions.

*40 Research Podium Presentations * 14 Workshops * 5 Issue Panels * Exhibits * 350 Research Poster Presentations – Session II * Evening Social Event

Wednesday, May 25: 8:00AM - 4:00PM
THIRD PLENARY SESSION: MODELING GOOD RESEARCH PRACTICES – EVERYTHING YOU NEED TO KNOW
ISPOR and the Society for Medical Decision Making (SMDM) are jointly developing a series of reports on good research practices (preferred practices) for modeling studies. These reports address contentious modeling issues, conceptual framework for modeling, discrete event simulation, state-based and dynamic transmission modeling, as well as transparency and validation of models. The ISPOR-SMDM recommendations for modeling preferred practices which address these contentious issues will be presented during this plenary session.

*10 Workshops * 5 Issue Panels * Exhibits * 350 Research Poster Presentations – Session III
ISPOR Member  Non-Member*

Standard
Registration Before April 5, 2011  US$650  US$790
Registration After April 5, 2011  US$750  US$890

Clinical Practitioners (Clinical Practice, Hospital)
Registration Before April 5, 2011  US$450  US$590
Registration After April 5, 2011  US$550  US$690

Full-Time Government and Academia
Registration Before April 5, 2011  US$350  US$490
Registration After April 5, 2011  US$450  US$590

Full-Time Students (must provide current enrollment documentation)
Registration Before April 5, 2011  US$150  US$185
Registration After April 5, 2011  US$200  US$235

One Day Registration (per day)** (One Day registrations cannot be combined)
May 23  May 24  May 25  US$350  US$400

Continuing Education Accreditation
US$100  US$100

ISPOR Social Event: Information to follow

REGISTRATION FEES

<table>
<thead>
<tr>
<th>QTY</th>
<th>FEE</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SHORT COURSES

SATURDAY, MAY 21, 2011
All Day Courses 8:00 AM – 5:00 PM
- Introduction to Pharmacoeconomics
- Bayesian Analysis – Overview and Applications

Morning Courses 8:00 AM – 12:00 PM
- Elements of Pharmaceutical/Biotech Pricing I – Introduction
- Introduction to Modeling
- NEW! Introduction to Multiple Regression Methods
- Cost-Effectiveness Analysis alongside Clinical Trials
- Introduction to Patient-Reported Outcomes

Afternoon Courses 1:00 PM – 5:00 PM
- Financial Impact / Cost of Illness
- Modeling: Design and Structure of a Model
- Meta-Analysis in Comparative Effectiveness Research
- NEW! Multiple Regression Methods for Outcomes Research with Observational Data
- Patient Registries

SUNDAY, MAY 22, 2011
All Day Course 8:00 AM – 5:00 PM
- Discrete Event Simulation for Economic Analyses

Morning Courses 8:00 AM – 12:00 PM
- Bayesian Analysis – Advanced
- Applications in Using Large Databases
- Patient-Reported Outcomes – Item Response Theory
- Conjoint Analysis – Theory & Methods
- Utility Measures
- Case Studies in Pharmaceutical/Biotech Pricing II – Advanced
- Statistical Considerations in Health Economic Evaluations

Afternoon Courses 1:00 PM – 5:00 PM
- Applications of Statistical Considerations in Health Economic Evaluations
- Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
- Outcomes Research for Medical Devices and Diagnostics
- Propensity Scores and Observational Studies of Treatment Effect
- Advanced Patient-Reported Outcomes Assessment – Psychometric Methods
- Establishing the Content Validity of Patient-Reported Outcome (PRO) Instruments
- Advanced Decision Modeling for Health Economic Evaluations

HALF DAY SHORT COURSE FEES

<table>
<thead>
<tr>
<th>REGISTRATION BEFORE APRIL 5, 2011</th>
<th>REGISTRATION AFTER APRIL 5, 2011</th>
</tr>
</thead>
</table>

ALL DAY SHORT COURSE FEES

<table>
<thead>
<tr>
<th>REGISTRATION BEFORE APRIL 5, 2011</th>
<th>REGISTRATION AFTER APRIL 5, 2011</th>
</tr>
</thead>
</table>

TOTAL REGISTRATION FEE: ___

PAYMENT INFORMATION

Please enclose a check payable in US dollars to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given below or charge to: VISA  MasterCard  American Express

Account Number:  Expiration Date:  

Name:  

Mail Details: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoeconomics and Outcomes Research, 3100 Princeton Pike, Building 3 Suite E, Lawrenceville, New Jersey 08648, USA  Tel: 1-609-219-0773  Fax: 1-609-219-0774  E-Mail: info@ispor.org  Internet: www.ispor.org

Payment Details: Payment may be made by check, travelers checks, bank transfer (there is a USD $40 charge) or credit card. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number and expiration date must be included. Non-US checks written in US $ on banks with a US counterpart are at no charge. For Non-US checks written in US $ on banks with NO US counterpart there is USD $25 charge. Phone charges will NOT be accepted.

If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence. For bank transfers, please designate the registration name and/or registration number.

* Membership Details: If ISPOR cannot verify your current membership, you will be charged the non-member registration rate. When you register as a non-member, you receive an ISPOR membership which includes a one year online subscription to Value in Health - The Journal of the International Society for Pharmacoeconomics and Outcomes Research.
** One Day Registration Details: One day registration does not include ISPOR membership benefits and cannot be combined.

Cancellation Details: Cancellation fee before April 5, 2011 is US $100. No refunds given after April 5, 2011.

FOR MORE INFORMATION: www.ispor.org